Holen Sie sich die Stockscreener-App
5.84
2.02%
0.11
Schlusskurs vom Vortag:
$5.73
Offen:
$5.73
24-Stunden-Volumen:
45,053
Relative Volume:
0.25
Marktkapitalisierung:
$342.12M
Einnahmen:
$24.52M
Nettoeinkommen (Verlust:
$-72.12M
KGV:
-4.9212
EPS:
-1.1867
Netto-Cashflow:
$-88.88M
1W Leistung:
+5.33%
1M Leistung:
-0.58%
6M Leistung:
+5.14%
1J Leistung:
+11.78%
1-Tages-Spanne:
$5.66
$5.91
1-Wochen-Bereich:
$5.217
$5.94
52-Wochen-Spanne:
$2.9448
$6.95
Foghorn Therapeutics Inc Stock (FHTX) Company Profile
Firmenname
Foghorn Therapeutics Inc
Sektor
Branche
Telefon
617-586-3100
Adresse
500 TECHNOLOGY SQUARE, CAMBRIDGE
Compare FHTX vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FHTX
Foghorn Therapeutics Inc
|
5.84 | 335.67M | 24.52M | -72.12M | -88.88M | -1.1867 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.79 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
788.49 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
835.73 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.93 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Foghorn Therapeutics Inc Stock (FHTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-17 | Fortgesetzt | Jefferies | Buy |
| 2025-12-18 | Eingeleitet | BTIG Research | Buy |
| 2025-11-07 | Eingeleitet | Guggenheim | Buy |
| 2025-09-17 | Fortgesetzt | B. Riley Securities | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2025-01-30 | Eingeleitet | B. Riley Securities | Buy |
| 2024-09-03 | Eingeleitet | Jefferies | Buy |
| 2024-08-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-03-28 | Eingeleitet | BofA Securities | Buy |
| 2023-01-05 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-11-22 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-11-17 | Eingeleitet | Cowen | Outperform |
| 2020-11-17 | Eingeleitet | Goldman | Buy |
| 2020-11-17 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-17 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Foghorn Therapeutics Inc Aktie (FHTX) Neueste Nachrichten
Foghorn Therapeutics names Ryan Maynard as chief financial officer - Investing.com
Foghorn Therapeutics (FHTX) Appoints New CFO with Extensive Expe - GuruFocus
Foghorn Therapeutics Appoints Ryan Maynard CFO - marketscreener.com
Foghorn Therapeutics Names Veteran Executive as New CFO - TipRanks
Foghorn Therapeutics Inc. Appoints Ryan Maynard as Chief Financial Officer - Quiver Quantitative
Biotech CFO who raised $1B in deals joins Foghorn Therapeutics - Stock Titan
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Qiagen (QGEN) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Investment Review: Does Aris Mining Corporation have a competitive edgeQuarterly Portfolio Summary & Verified Entry Point Detection - baoquankhu1.vn
Jefferies Financial Group Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Jefferies Lowers Price Target for Foghorn Therapeutics (FHTX) to $12.00 | FHTX Stock News - GuruFocus
Jefferies initiates Foghorn Therapeutics stock with buy rating By Investing.com - Investing.com Nigeria
Jefferies initiates Foghorn Therapeutics stock with buy rating - Investing.com
Can Foghorn Therapeutics Inc. stock double in the next yearProduct Launch & High Accuracy Investment Signals - mfd.ru
Foghorn Therapeutics appoints interim CFO Jeff Sacher - MSN
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Average Rating of “Buy” from Brokerages - Defense World
Foghorn Therapeutics CEO Talks Lilly-Partnered SMARCA2 Phase 1 and New Degrader Targets at Conference - MarketBeat
Does Foghorn Therapeutics Inc. have strong fundamentalsWeekly Trade Report & Verified Short-Term Plans - mfd.ru
Foghorn Therapeutics (NASDAQ:FHTX) Stock Price Down 0.6%Should You Sell? - MarketBeat
Foghorn Therapeutics: Key Catalysts on the Horizon for Investors - AD HOC NEWS
Foghorn Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit - Investing News Network
Flagship Pioneering Appoints Paul Owen as CEO-Partner and CEO of YourBio Health - Quantisnow
Foghorn Therapeutics Reports Q3 2025 Financial Results - MSN
Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics - Quantisnow
Foghorn Therapeutics (NASDAQ:FHTX) Shares Down 4.1%Time to Sell? - MarketBeat
Highs Report: Can Foghorn Therapeutics Inc maintain sales growth2025 Market WrapUp & AI Powered Buy and Sell Recommendations - baoquankhu1.vn
Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff - Benzinga
Foghorn Therapeutics stock reaffirmed as Buy by BTIG, named top pick for 1H26 - Investing.com Canada
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium - GlobeNewswire
Stifel reiterates Buy rating on Foghorn Therapeutics stock at $12 target - Investing.com Canada
Foghorn Therapeutics Announces $50 Million Equity Financing - TipRanks
Is Foghorn Therapeutics (NASDAQ:FHTX) In A Good Position To Deliver On Growth Plans? - Yahoo Finance
Insider Trends: Will Foghorn Therapeutics Inc stock benefit from green energy trendsJuly 2025 Review & Real-Time Stock Movement Alerts - Bộ Nội Vụ
What momentum indicators show for Foghorn Therapeutics Inc. stockJuly 2025 Catalysts & Safe Entry Trade Signal Reports - ulpravda.ru
Foghorn Therapeutics Inc. Secures $50 Million in Equity Financing to Advance Oncology Pipeline and Strengthen Balance Sheet - Quiver Quantitative
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026 - Yahoo Finance
Biotech raises $50M to push new lung and breast cancer drugs forward - Stock Titan
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic ... - Bluefield Daily Telegraph
Will Foghorn Therapeutics Inc. stock benefit from green energy trends - Улправда
Can Foghorn Therapeutics Inc. stock sustain free cash flow growthWeekly Investment Report & High Accuracy Trade Signal Alerts - Улправда
Can Foghorn Therapeutics Inc. stock reach $100 price targetEarnings Beat Highlights & Swing Trade Smarter With Data Insights - bollywoodhelpline.com
Why Foghorn Therapeutics Inc. stock is recommended by analystsRisk-Reward Ratio Analysis & Small Budget Big Profits - Улправда
Will Foghorn Therapeutics Inc. stock continue upward momentumBull Market Opportunities & Outstanding Wealth Building - ulpravda.ru
Is Foghorn Therapeutics Inc. stock a bargain at current levels2026 world cup usa national team group stage top scorers possession football odds analysis expert opinion - Улправда
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX) and Foghorn Therapeutics (FHTX) - The Globe and Mail
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Stock Rockets 25% As Investors Are Less Pessimistic Than Expected - simplywall.st
Can Foghorn Therapeutics Stock Hold Up When Markets Turn? - Trefis
Is Foghorn Therapeutics Inc. stock resilient to inflation2025 Support & Resistance & Real-Time Chart Breakout Alerts - Улправда
BTIG Research Begins Coverage on Foghorn Therapeutics (NASDAQ:FHTX) - Defense World
Finanzdaten der Foghorn Therapeutics Inc-Aktie (FHTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.88%
0.83%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):